Diabetes in People with HIV

Overview

Journal Curr Diab Rep

Publisher Current Science

Specialty Endocrinology

Date 2021 Mar 17

PMID 33730223

Citations 15

Authors

Sudipa Sarkar

Todd T Brown

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: To discuss the diagnosis, treatment, and complications of diabetes in people with HIV (PWH) and to review HIV-related factors that may contribute to the development of diabetes or alter decisions in the care and treatment of PWH with diabetes.

Recent Findings: For those patients with atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, GLP-1 receptor agonists and SGLT-2 inhibitors should be considered for use. Evidence for this recommendation is, however, based on studies that were not conducted in populations consisting solely of PWH. Diabetes is a significant comorbidity in PWH and adds to their already heightened risk of cardiovascular disease. HIV-specific factors, including interactions of antiretroviral therapy with medications that either treat diabetes and/or prevent cardiovascular disease, should be evaluated.

Citing Articles

Impact of Depression and HIV Symptoms on Glycemic Outcomes among Patients with HIV and Type 2 Diabetes: A Clinical Cohort Study.

Brady V, Willig A, Christopoulos K, Grelotti D, Yendewa G, OCleirigh C AIDS Behav. 2025; .

PMID: 39961951 DOI: 10.1007/s10461-025-04653-7.

Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.

Anaya-Ambriz E, Alvarez-Zavala M, Gonzalez-Hernandez L, Andrade-Villanueva J, Zuniga-Quinones S, Valle-Rodriguez A Int J Mol Sci. 2025; 26(3).

PMID: 39940683 PMC: 11817432. DOI: 10.3390/ijms26030914.

Nutritional risk and HbA1c as critical risk factors and predictors of opportunistic infections in HIV-DM comorbid patients: a retrospective cross-sectional study.

Zhu Q, Gao F, Ren X, Li R, Kang J, Li M Front Endocrinol (Lausanne). 2025; 15:1527936.

PMID: 39866736 PMC: 11757115. DOI: 10.3389/fendo.2024.1527936.

HIV clinical outcomes among people with HIV and diabetes mellitus in Kampala, Uganda; A matched retrospective cohort study.

Nakalega R, Semitala F, Mutebi E, Mawanda D, Lukyamuzi Z, Menge R PLOS Glob Public Health. 2025; 5(1):e0003922.

PMID: 39820139 PMC: 11737773. DOI: 10.1371/journal.pgph.0003922.

Indicators associated with severity and mortality in hospitalized people with HIV: A retrospective cohort.

Ziani J, Harter J, Monteiro F, Dalcin C, de Mello Padoin S, Primeira M Rev Bras Enferm. 2025; 77(6):e20240204.

PMID: 39813525 PMC: 11731855. DOI: 10.1590/0034-7167-2024-0204.

References

Grinspoon S, Fitch K, Overton E, Fichtenbaum C, Zanni M, Aberg J . Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019; 212:23-35. PMC: 6535121. DOI: 10.1016/j.ahj.2018.12.016. View

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

Garcia de Lucas M, Olalla Sierra J, Pina Fernandez J . Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome. Diabetes Metab. 2014; 41(1):102-3. DOI: 10.1016/j.diabet.2014.10.005. View

Slama L, Lanoy E, Valantin M, Bastard J, Chermak A, Boutekatjirt A . Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther. 2008; 13(1):67-76. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A . Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012; 97(9):3333-41. PMC: 3431580. DOI: 10.1210/jc.2012-1544. View

. 11. Microvascular Complications and Foot Care: . Diabetes Care. 2019; 43(Suppl 1):S135-S151. DOI: 10.2337/dc20-S011. View

Goldberg D, Smithen L, Angelilli A, Freeman W . HIV-associated retinopathy in the HAART era. Retina. 2005; 25(5):633-49. DOI: 10.1097/00006982-200507000-00015. View

Gelpi M, Afzal S, Fuchs A, Lundgren J, Knudsen A, Drivsholm N . Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factors. AIDS. 2018; 33(4):675-683. DOI: 10.1097/QAD.0000000000002119. View

10.

Kaarsholm N, Lin S, Yan L, Kelly T, van Heek M, Mu J . Engineering Glucose Responsiveness Into Insulin. Diabetes. 2017; 67(2):299-308. DOI: 10.2337/db17-0577. View

11.

Palella Jr F, Li X, Gupta S, Estrella M, Phair J, Margolick J . Long-term kidney function, proteinuria, and associated risks among HIV-infected and uninfected men. AIDS. 2018; 32(10):1247-1256. PMC: 7406064. DOI: 10.1097/QAD.0000000000001807. View

12.

Han J, Gordon K, Womack J, Gibert C, Leaf D, Rimland D . Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans. Diabetes Care. 2016; 40(2):218-225. PMC: 5250696. DOI: 10.2337/dc16-0718. View

13.

Schuelter-Trevisol F, Wolff F, Alencastro P, Grigoletti S, Ikeda M, Brandao A . Physical activity: do patients infected with HIV practice? How much? A systematic review. Curr HIV Res. 2012; 10(6):487-97. DOI: 10.2174/157016212802429794. View

14.

Eckard A, McComsey G . Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2019; 33(1):10-19. PMC: 7433018. DOI: 10.1097/QCO.0000000000000616. View

15.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

16.

Hinnen D . Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr. 2017; 30(3):202-210. PMC: 5556578. DOI: 10.2337/ds16-0026. View

17.

Prioreschi A, Munthali R, Soepnel L, Goldstein J, Micklesfield L, Aronoff D . Incidence and prevalence of type 2 diabetes mellitus with HIV infection in Africa: a systematic review and meta-analysis. BMJ Open. 2017; 7(3):e013953. PMC: 5372101. DOI: 10.1136/bmjopen-2016-013953. View

18.

Filipova E, Uzunova K, Kalinov K, Vekov T . Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis. Diabetes Ther. 2017; 8(4):705-726. PMC: 5544610. DOI: 10.1007/s13300-017-0273-4. View

19.

Calmy A, Hirschel B, Hans D, Karsegard V, Meier C . Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS. 2003; 17(5):770-2. DOI: 10.1097/00002030-200303280-00022. View

20.

Lewis J, Habel L, Quesenberry C, Strom B, Peng T, Hedderson M . Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA. 2015; 314(3):265-77. DOI: 10.1001/jama.2015.7996. View